IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress

Core Insights - Iovance Biotherapeutics reported a narrower loss of 18 cents per share for Q4 2025, compared to a loss of 26 cents in the same quarter last year, and better than the Zacks Consensus Estimate of a loss of 22 cents [1][6] - Total revenues for Q4 increased by 17.6% year over year to $87 million, surpassing the Zacks Consensus Estimate of $75 million [1][6] Revenue Breakdown - Iovance has two marketed drugs: Proleukin and Amtagvi. Proleukin generated $22 million in Q4, down 12% year over year, while Amtagvi sales reached approximately $65 million, a 33.4% increase year over year, exceeding the Zacks Consensus Estimate of $61 million [2][3] Operating Costs - Research and development expenses were $71.2 million in Q4, a slight increase of 0.3% from the previous year. Selling, general, and administrative expenses decreased by 14% to $36.4 million due to lower stock compensation expenses [4] Financial Position - Iovance reported a gross margin of 50% in Q4, up from 43% in the previous quarter, attributed to improved operational efficiency following a restructuring plan [5] - As of December 31, 2025, the company had cash and investments totaling $303 million, down from $307 million as of September 30, 2025, with expectations to fund operations into Q3 2027 [5] Full-Year Performance - For the full year 2025, Iovance reported total revenues of approximately $264 million, a 61% increase year over year, and a net loss per share of $1.09, an improvement from a loss of $1.28 per share in 2024 [6] Pipeline Developments - Iovance announced positive early-stage study results for Amtagvi in advanced undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS), with an objective response rate (ORR) of 50% [7][9] - The company plans to initiate a registrational study for Amtagvi in second-line advanced UPS and DDLPS in Q2 2026 and is engaging with the FDA regarding a potential regulatory pathway [9] Market Response - Following the announcement of Q4 results and positive study data, Iovance shares rose by 31%. However, the stock has declined by 29.2% over the past year, contrasting with the industry's growth of 18.8% [10]